New Partnership to Provide Bioanalytical and DMPK Services
Concept Life Sciences (“Concept”), the integrated drug discovery, development and analytical services company, and Alderley Analytical, the GLP/GCP compliant, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.
Under the terms of the agreement, Concept will gain access to Alderley Analytical’s significant expertise in bioanalysis, and Alderley Analytical will benefit from Concept’s deep understanding of synthetic, organic and medicinal chemistry, biology, toxicology, and analytical services. The combined offering will give clients of both companies, including biotech, pharma and agrochemicals companies, access to industry-leading assay development services for quantification of new molecules in a biological matrix, using the most sensitive instrumentation available.
Michael Fort, Executive Chairman, Concept Life Sciences, commented: “The team at Alderley Analytical has built an impressive reputation for delivery of the highest quality GLP/GCP bioanalytical services. Combining this offering with our Group’s expertise, including the recent additions of translational biology and large molecule research, brings benefits to the widest group of life sciences clients.”
This article has been republished from materials provided by Concept Life Sciences. Note: material may have been edited for length and content. For further information, please contact the cited source.
Antitumor Immune Function in Liver Controlled by Gut MicrobiomeNews
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. The study showed that bacteria found in the gut of mice affect the liver’s antitumor immune function. The findings have implications for understanding the mechanisms that lead to liver cancer and for therapeutic approaches to treat them.READ MORE
Tiny Particles Carry Tumor Shrinking Drugs into the BrainNews
MIT researchers have now devised a new drug-delivering nanoparticle that could offer a better way to treat glioblastoma. The particles, which carry two different drugs, are designed so that they can easily cross the blood-brain barrier and bind directly to tumor cells.READ MORE
Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous SclerosisNews
Addressing a critical issue for people with a genetic disorder called tuberous sclerosis complex (TSC), doctors reported that a skin cream containing rapamycin significantly reduced the disfiguring facial tumors affecting more than 90 percent of people with the condition.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018